Optimal management of taxane acute pain syndrome not clear

the ONA take:

Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched with few studies have evaluated its optimal management, according to a systematic review published online ahead of print in the journal Supportive Care in Cancer.

TAPS is characterized by myalgias and arthralgias beginning 1 to 3 days and lasting 5 to 7 days after taxane-based chemotherapy.

Although it is known to negatively impact patients’ quality of life, the optimal management of TAPS is unclear.

Therefore, researchers at The Ottawa Hospital and University of Ottawa in Ontario, Canada, conducted a systematic review of treatment strategies for TAPS across all tumor sites.

Results showed that neither glutathione nor glutamine were superior to placebo for TAPS. Researchers found that amifostine, a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy, reduced pain in 36% of patients, while gabapentin reduced taxane-induced arthralgias and myalgias in 90% of patients.

“If the management of patients is to be improved, more prospective trials are needed,” the authors conclude.

Managing peripheral neuropathy
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome remains poorly researched.
Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 1-3 days and lasting 5-7 days after taxane-based chemotherapy. Despite negatively impacting patient's quality of life, little is known about the optimal TAPS management. A systematic review of treatment strategies for TAPS across all tumor sites was performed.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs